Premium
Microcontainer Delivery of Antibiotic Improves Treatment of Pseudomonas aeruginosa Biofilms
Author(s) -
Birk Stine Egebro,
Haagensen Janus Anders Juul,
Johansen Helle Krogh,
Molin Søren,
Nielsen Line Hagner,
Boisen Anja
Publication year - 2020
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201901779
Subject(s) - biofilm , pseudomonas aeruginosa , antibiotics , ciprofloxacin hydrochloride , microbiology and biotechnology , ciprofloxacin , chitosan , chemistry , drug delivery , bacteria , biology , biochemistry , genetics , organic chemistry
Biofilm‐associated infections are difficult to treat effectively with antibiotics despite repeated treatments. Polymeric microdevices (microcontainers) have previously been shown to engulf in mucus layers and to provide tunable release. Such devices may overcome the challenge of delivering antibiotics into the biofilm, increasing the local drug concentration and hence improve local bacterial killing. In this work, microcontainers are loaded with the antibiotic, ciprofloxacin hydrochloride, and functionalized with polymeric lids of polyethylene glycol (PEG), chitosan, or Eudragit S100. The PEG lid gives rise to a drug release comparable to uncoated microcontainers showing complete release after 8 h, whereas chitosan and Eudragit S100 lids result in continuous release during the course of 24 h. All antibiotic‐containing microcontainers inhibit planktonic growth of Pseudomonas aeruginosa (PAO1) cells, but the degree of inhibition depends on the coating. Microcontainers with ciprofloxacin hydrochloride kill about three times more biofilm‐associated PAO1 cells compared with a single standard bolus. Moreover, the use of microcontainers in biofilm result in bacterial killing equal to a constant flow of a three times higher concentration of solubilized antibiotics. These studies suggest that microcontainers can be useful for antibiotic delivery in treatment of biofilm‐associated infections, resulting in more effective treatment and reduced use of antibiotics.